This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Study of CX157 (TriRima) for the Treatment of Depression (CX157-200)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
CeNeRx BioPharma Inc.
ClinicalTrials.gov Identifier:
NCT00739908
First received: August 20, 2008
Last updated: June 26, 2012
Last verified: June 2012
History of Changes
Results First Received: February 14, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Major Depressive Disorder
Interventions: Drug: CX157 (TriRima)
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
The study was conducted at 14 out-patient medical centers in the United States (US) from 16 September 2008 (date of first subject randomized) to 09 July 2009 (last subject’s last visit).

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
A total of 587 subjects were screened. Three hundred and two (302) subjects failed to meet study entry criteria, and thus were screen failures. The top three reasons for screen failure were: IDS-SR30 total score cut-off for randomization not met (204 pts); presence of cardiovascular abnormality (18 pts) and Laboratory Abnormalities (14 pts).

Reporting Groups
  Description
Oral CX157 60 mg TID (Total Daily Dose of 180 mg) CX157 is an investigational compound. The mechanism of action of this compound is Reversible Monoamine oxidase inhibition (MAOI)
Oral Placebo TID Placebo does not have any active medication and is the same as a Sugar Pill.

Participant Flow:   Overall Study
    Oral CX157 60 mg TID (Total Daily Dose of 180 mg)   Oral Placebo TID
STARTED   142   143 
COMPLETED   117   118 
NOT COMPLETED   25   25 
Adverse Event                5                6 
Withdrawal by Subject                4                2 
Lost to Follow-up                14                9 
Non-Compliance With Study Procedures                2                3 
Non-Compliance With Study Medication                0                3 
Lack of Efficacy                0                1 
Relocation                0                1 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Oral CX157 60 mg TID (Total Daily Dose of 180 mg) CX157 is an investigational compound. The mechanism of action of this compound is Reversible Monoamine oxidase inhibition (MAOI)
Oral Placebo TID Placebo does not have any active medication and is the same as a Sugar Pill.
Total Total of all reporting groups

Baseline Measures
   Oral CX157 60 mg TID (Total Daily Dose of 180 mg)   Oral Placebo TID   Total 
Overall Participants Analyzed 
[Units: Participants]
 		 142   143   285 
Age 
[Units: Participants]
 		     
<=18 years   0   5   5 
Between 18 and 65 years   142   138   280 
>=65 years   0   0   0 
Age 
[Units: Years]
Mean (Standard Deviation) 		 39.1  (11.14)   38.5  (11.16)   38.8  (11.14) 
Gender 
[Units: Participants]
 		     
Female   80   81   161 
Male   62   62   124 
Race (NIH/OMB) 
[Units: Participants]
 		     
American Indian or Alaska Native   3   2   5 
Asian   3   2   5 
Native Hawaiian or Other Pacific Islander   0   0   0 
Black or African American   30   32   62 
White   102   105   207 
More than one race   0   0   0 
Unknown or Not Reported   4   2   6 
Region of Enrollment 
[Units: Participants]
 		     
United States   142   143   285 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change From Randomization in Montgomery and Asberg Depression Rating Scale (MADRS)   [ Time Frame: Randomization and study end (Week 6). ]
  Show Outcome Measure 1

2.  Secondary:   Montgomery and Asberg Depression Rating Scale (MADRS) Response Rate   [ Time Frame: Week 6 or the last available post treatment result (LOCF) ]
  Show Outcome Measure 2

3.  Secondary:   Montgomery and Asberg Depression Rating Scale (MADRS) Remitter Rate   [ Time Frame: Week 6 or the last available post treatment result (LOCF) ]
  Show Outcome Measure 3

4.  Secondary:   The Hospital Anxiety and Depression Scale (HADS)   [ Time Frame: Randomization and Week 6 or the last available post treatment result (LOCF) ]
  Show Outcome Measure 4

5.  Secondary:   Inventory of Depressive Symptomatology 30 Item -Self Report (IDS -SR 30 Items)   [ Time Frame: Randomization and Week 6 or the last available post treatment result (LOCF) ]
  Show Outcome Measure 5

6.  Secondary:   Clinical Global Impression - Improvement of Illness (CGI-I)   [ Time Frame: Week 6 or the last available post treatment result (LOCF) ]
  Show Outcome Measure 6

7.  Secondary:   Clinical Global Impression - Severity of Illness (CGI-S)   [ Time Frame: Week 6 or the last available post treatment result (LOCF) ]
  Show Outcome Measure 7


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Subjects were asked to take 6 capsules 3 times a day for 6 weeks. Non-adherence with the study medication was high based on the population PK data. This likely contributed to the results in CX157 treatment group.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Mahnaz Asgharnejad, Pharm.D.; Daniel Burch, M.D.
Organization: CeNeRx BioPharma Inc.
phone: (919) 655 1435; (919) 674 6041
e-mail: masgharnejad@cenerx.com; danburch@cenerx.com



Responsible Party: CeNeRx BioPharma Inc.
ClinicalTrials.gov Identifier: NCT00739908     History of Changes
Other Study ID Numbers: CX157-200
Study First Received: August 20, 2008
Results First Received: February 14, 2012
Last Updated: June 26, 2012